Recursion Pharmaceuticals, Inc. (RXRX)
USD 6.22
(-12.71%)
USD 6.22
(-12.71%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 44.57 Million | 39.68 Million | 10 Million | 3.41 Million | 1.71 Million |
| Cost of Revenue | 42.58 Million | 48.27 Million | 9.1 Million | 63.31 Million | 45.8 Million |
| Gross Profit | 1.98 Million | -8.59 Million | 896 Thousand | -59.9 Million | -44.09 Million |
| Operating Expenses | 352.04 Million | 237.13 Million | 192.77 Million | 88.02 Million | 64.15 Million |
| Selling, General and Administrative Expenses | 110.82 Million | 81.59 Million | 57.68 Million | 25.25 Million | 18.95 Million |
| Research and Development Expenses | 241.22 Million | 155.69 Million | 135.27 Million | 63.31 Million | 45.8 Million |
| Other Expenses | - | -162 Thousand | -178 Thousand | -549 Thousand | -608 Thousand |
| Cost and Expenses | 394.63 Million | 285.4 Million | 192.77 Million | 88.02 Million | 64.15 Million |
| Operating Income | -350.06 Million | -245.72 Million | -182.77 Million | -84.61 Million | -62.44 Million |
| Interest Expense | 97 Thousand | 55 Thousand | 2.95 Million | 1.36 Million | 635 Thousand |
| Income Tax Expense | -4.06 Million | -55 Thousand | -8.4 Million | 876 Thousand | 646 Thousand |
| Earnings before Tax | -332.12 Million | -239.47 Million | -186.47 Million | -87 Million | -61.87 Million |
| Net Income | -328.06 Million | -239.42 Million | -178.07 Million | -87.88 Million | -62.52 Million |
| Earnings Per Share Basic | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Earnings Per Share Diluted | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Weighted Average Shares Outstanding | 207.85 Million | 175.53 Million | 170.27 Million | 165.79 Million | 165.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 207.85 Million | 175.53 Million | 170.27 Million | 165.79 Million | 165.79 Million |
| Gross Margin | 0.04 | -0.22 | 0.09 | -17.55 | -25.77 |
| EBIT Margin | -6.72 | -6.19 | -18.28 | -23.53 | -34.02 |
| Profit Margin | -7.36 | -6.03 | -17.81 | -25.75 | -36.54 |
| EBITDA | -299.56 Million | -227.66 Million | -174.42 Million | -81.7 Million | -58.33 Million |
| Earnings Before Tax Margin | -7.85 | -6.19 | -18.28 | -24.79 | -36.49 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 14.41 Million | 13.79 Million | 10.89 Million | 44.57 Million | 10.1 Million | 11.01 Million |
| Cost of Revenue | 13.09 Million | 14.56 Million | 23.48 Million | 51.08 Million | 10.87 Million | 9.38 Million |
| Gross Profit | 1.31 Million | -772 Thousand | -12.59 Million | -6.51 Million | -775 Thousand | 1.63 Million |
| Operating Expenses | 101.86 Million | 95.56 Million | 96.54 Million | 343.54 Million | 98.77 Million | 83.34 Million |
| Selling, General and Administrative Expenses | 31.83 Million | 31.4 Million | 30.45 Million | - | 29.19 Million | 28.29 Million |
| Research and Development Expenses | 70.02 Million | 64.16 Million | 66.08 Million | - | 70 Million | 55.06 Million |
| Other Expenses | -392 Thousand | 160 Thousand | -2.62 Million | -1.08 Million | 1.58 Million | 4.98 Million |
| Cost and Expenses | 114.96 Million | 110.13 Million | 120.02 Million | 394.63 Million | 109.65 Million | 92.73 Million |
| Operating Income | -100.54 Million | -96.34 Million | -109.13 Million | -350.06 Million | -99.55 Million | -81.71 Million |
| Interest Expense | 394 Thousand | 20 Thousand | 26 Thousand | 97 Thousand | 25 Thousand | 26 Thousand |
| Income Tax Expense | -523 Thousand | -779 Thousand | -1.62 Million | -4.06 Million | 1.6 Million | -5.54 Million |
| Earnings before Tax | -98.06 Million | -92.15 Million | -94.62 Million | -332.12 Million | -93.01 Million | -76.72 Million |
| Net Income | -97.54 Million | -91.37 Million | -92.99 Million | -328.06 Million | -93.01 Million | -76.72 Million |
| Earnings Per Share Basic | -0.40 | -0.39 | -0.40 | - | -0.43 | -0.38 |
| Earnings Per Share Diluted | -0.40 | -0.39 | -0.40 | - | -0.43 | -0.38 |
| Weighted Average Shares Outstanding | 242.19 Million | 236.01 Million | 233.15 Million | 207.85 Million | 214.32 Million | 201.41 Million |
| Weighted Average Shares Outstanding (Diluted) | 242.19 Million | 236.01 Million | 233.15 Million | 207.85 Million | 214.32 Million | 201.41 Million |
| Gross Margin | 0.09 | -0.06 | -1.16 | -0.15 | -0.08 | 0.15 |
| EBIT Margin | -6.42 | -6.45 | -8.59 | - | -8.46 | -7.42 |
| Profit Margin | -6.77 | -6.62 | -8.54 | -7.36 | -9.21 | -6.96 |
| EBITDA | -92.54 Million | -88.94 Million | -93.51 Million | - | -85.41 Million | -81.71 Million |
| Earnings Before Tax Margin | -6.97 | -6.98 | -10.02 | -7.85 | -9.85 | -7.42 |
603606
MANAPPURAM
287410
688272
005965
CIBEY